Time filter

Source Type

Chicago, IL, United States

Vancive Medical Technologies | Entity website

Sustainability is rooted in our company values and has long been part of our approach to business. Today, it drives us to work collaboratively across our entire value chain to address the environmental and social impacts of medical products ...

Vancive Medical Technologies | Entity website

Vancive Medical Technologies | Entity website

GLENDALE, Calif.--(BUSINESS WIRE)--Calling climate change an imminent global threat that demands urgent action from all segments of society,Avery Dennison Corporation(NYSE: AVY) announced today that it has signed the American Business Act on Climate Pledge, a White House initiative to enlist U ...

Stephen-Haynes J.,City University London | Callaghan R.,Worcestershire Health and Care NHS Trust | Wibaux A.,Vancive Medical Technologies | Johnson P.,Vancive Medical Technologies | Carty N.,Vancive Medical Technologies
Journal of Wound Care | Year: 2014

Objective: This article assesses the use of BeneHold Thin Absorbent Skin Adhesive (TASA) wound dressings in a large UK primary care organisation. These wound dressings are thin (0.12mm), breathable, transparent, and are able to absorb and retain wound exudate. This non-comparative evaluation was undertaken to explore the clinical advantages this differentiated combination of physical properties offered. Method: The dressings are CE-marked medical devices, and were used on patients with acute and chronic wounds that were assessed and classified as light to moderately exuding. Clinical performance was evaluated with respect to the dressing's ease of use (application and removal, conformability, mould-ability, rolling and edge-lift), debridement, protection of the peri-wound, wear time, fluid handling, wound bed residue, visibility of the wound, and clinical acceptability. The evaluating clinicians used an agreed audit tool to collect data from case reports to document the progression of wounds of various aetiologies, including chronic and acute, for a maximum period of four weeks. Qualitative feedback on dressing performance was also collected at the evaluation's end, both from the clinicians' and patients' perspectives Results: Some 15 patients were assessed. The wear time was up to seven days in many cases, and on average was 3.9 days longer than their previous dressings. Clinicians perceived that wounds progressed toward healing in all but two cases, where the wounds remained unchanged. Out of five cases where wounds presented with necrosis, all underwent significant autolytic debridement underneath the new dressings. Transparency was a noted benefit from both the clinicians' and patients' perspectives because it enabled continuous monitoring of the full wound bed and peri-wound skin without the need to disrupt the dressing. Conclusion: The dressing was well-received by both clinicians and patients in all fifteen cases. The thin absorbent skin adhesive dressing was found to be a promising new technology that could offer significant advantages to improve the quality, cost, and convenience of wound care. Further work is underway to validate these findings in larger and more homogeneous patient groups. © 2014 MA HEALTHCARE LTD Source

Bertram T.A.,RegeMedTX | Johnson P.C.,Vancive Medical Technologies | Tawil B.J.,University of California at Los Angeles | Van Dyke M.,Virginia Polytechnic Institute and State University | Hellman K.B.,Hellman Group
Tissue Engineering - Part A | Year: 2015

TERMIS-AM Industry Committee (TERMIS-AM/IC), in collaboration with the TERMIS-Europe (EU)/IC, conducted a symposium involving the European Medicines Agency and the U.S. Food and Drug Administration (FDA) toward building an understanding of the rational basis for regulatory decision-making and providing a framework for decisions made during the evaluation of safety and efficacy of TE/RM technologies. This symposium was held in August 2012 during the TERMIS-WC in Vienna, Austria. Emerging from this international initiative by the European Union and the United States, representatives from the respective agencies demonstrated that there are ongoing interagency efforts for developing common national practices toward harmonization of regulatory requirements for the TE/RM products. To extend a broad-based understanding of the role of science in regulatory decision-making, TERMIS-AM/IC, in cooperation with the FDA, organized a symposium at the 2014 TERMIS-AM Annual Meeting, which was held in Washington, DC. This event provided insights from leaders in the FDA and TERMIS on the current status of regulatory approaches for the approved TE/RM products, the use of science in making regulatory decisions, and TE/RM technologies that are in the development pipeline to address unmet medical needs. A far-ranging discussion with FDA representatives, industrialists, physicians, regenerative medicine biologists, and tissue engineers considered the gaps in today's scientific and regulatory understanding of TE/RM technologies. The identified gaps represent significant opportunities to advance TE/RM technologies toward commercialization. © Mary Ann Liebert, Inc. 2015. Source

Discover hidden collaborations